Back to NewsletterNewsletter

    The Lp(a) drug worked and prevented nothing, acarbose's human trials, and a frailty stem-cell RCT: new at Peak Human

    Physician edition, week of November 16, 2026: Lp(a)HORIZON in full, what to treat when Lp(a) is high, surrogate endpoints, acarbose, laromestrocel and tesamorelin.

    Nov 16, 20268 min read

    A note from Dr. Goel

    Colleagues, here is what's new at Peak Human this week. It was a lipoprotein(a) week. The full Lp(a)HORIZON results landed at AHA, and I wrote three pieces in response: what the trial actually showed, what we can still do for the patient whose Lp(a) is high, and the broader lesson about biomarkers that predict disease but turn out not to be treatment targets. The database also picked up three evidence refreshes that family physicians and internists will get asked about: acarbose, an allogeneic stem-cell trial in frailty, and a tesamorelin meta-analysis.

    Every link below goes to the specific page on peakhuman.ai. Everything here is a summary of published research, not a recommendation to start, stop or prescribe anything.

    In this issue:

    Lp(a)HORIZON in full: pelacarsen lowered Lp(a) by 78% and prevented nothing (Nov 12)

    High Lp(a): what actually lowers risk while we wait (Nov 13)

    When a biomarker isn't a target: the surrogate-endpoint graveyard (Nov 15)

    Acarbose: diabetes prevention, not cardiovascular protection (updated Nov 15)

    Stem cell therapy: a 148-patient randomized frailty trial (updated Nov 13)

    Peptide therapy: tesamorelin meta-analysis, and why it doesn't transfer (updated Nov 12)

    Also refreshed: acetyl-L-carnitine, plasma ceramides, copper-to-zinc ratio

    CLINICAL SPOTLIGHT, NEW ARTICLE NOV 12: Lp(a)HORIZON: the drug worked, the hypothesis didn't

    The full results were presented at AHA 2026 and published in NEJM. In 8,322 patients with prior MI, ischemic stroke or symptomatic PAD and Lp(a) of at least 70 mg/dL, pelacarsen cut Lp(a) by 78.4% at 12 months (median roughly 236 to 64 nmol/L) against 3.2% on placebo. Over a median 4.7 years, the primary composite occurred in 12.3% on pelacarsen and 12.1% on placebo (HR 1.02, 95% CI 0.90 to 1.15). No secondary endpoint or prespecified subgroup moved, including the highest-Lp(a) stratum.

    The safety data deserve as much attention as the efficacy. Adjudicated anaphylaxis occurred in 19 pelacarsen patients and none on placebo, and 20.6% stopped the drug permanently for adverse events versus 7.5% on placebo. The article is careful about what this does not show: it does not refute Lp(a) as a causal risk factor, and it did not test primary prevention. Olpasiran (OCEAN(a)-Outcomes) and lepodisiran (ACCLAIM-Lp(a)) are still running, with completion dates in 2028 and 2029.

    NEW ARTICLE NOV 13: High Lp(a)? What actually lowers risk

    This is the piece for the patient in front of you. Lp(a) is genetically fixed and has no approved therapy, so the article shifts the conversation to what Lp(a) multiplies: apoB-containing lipoproteins and blood pressure. In the FOURIER subgroup analysis, patients with higher Lp(a) needed roughly 40 treated for three years to prevent one event, versus about 105 with lower Lp(a); the interaction P value was 0.07, so treat that as hypothesis-generating. The article anchors on the meta-analytic numbers you already use: about 22% fewer major vascular events per 1.0 mmol/L LDL-C reduction (Cholesterol Treatment Trialists), and about 9% fewer per 5 mm Hg systolic reduction across most adult age groups. It also notes that statins modestly raise Lp(a), which is not a reason to stop them, and makes the case for cascade testing in first-degree relatives.

    NEW ARTICLE NOV 15: When a biomarker isn't a target

    Lp(a)HORIZON joins a long list. In ACCELERATE, evacetrapib raised HDL-C by 133% and lowered LDL-C by 31%, and cardiovascular events occurred in 12.9% versus 12.8% on placebo. Torcetrapib (ILLUMINATE) raised mortality. Niacin added to statins (AIM-HIGH, HPS2-THRIVE) added harm, not benefit. CAST showed that suppressing ventricular ectopy increased mortality, and HOPE-2 lowered homocysteine without lowering events. The article's rule is simple: a biomarker earns target status only when moving it in a randomized trial also moves hard outcomes. LDL-C passed that test across 26 trials; HDL-C never did, and Mendelian randomization agrees. Until then, a marker is for estimating risk, not for choosing drugs.

    EVIDENCE PAGE UPDATED NOV 15: Acarbose: diabetes prevention, not cardiovascular protection

    Acarbose keeps circulating in longevity forums because of mouse lifespan data from the NIA Interventions Testing Program. The refreshed page puts the human trials first. In STOP-NIDDM (Lancet 2002; 1,429 adults with impaired glucose tolerance, mean 3.3 years), progression to type 2 diabetes fell from 42% to 32% (HR 0.75, 95% CI 0.63 to 0.90). The widely quoted 49% reduction in cardiovascular events was a secondary analysis (JAMA 2003) with a wide interval. The dedicated outcomes trial, ACE (Lancet Diabetes and Endocrinology 2017; 6,522 Chinese adults with coronary disease and impaired glucose tolerance, median 5 years), confirmed 18% less incident diabetes (RR 0.82) but found no reduction in major adverse cardiovascular events (HR 0.98, 95% CI 0.86 to 1.11). The page is explicit that the longevity rationale in humans remains indirect, and lists the contraindications (inflammatory bowel disease, obstruction, cirrhosis).

    EVIDENCE PAGE UPDATED NOV 13: Stem cell therapy: a randomized frailty trial, and what it does not license

    The stem cell page now carries the phase 2b dose-escalation trial of laromestrocel, an investigational allogeneic bone-marrow mesenchymal cell product (Cell Stem Cell 2026; NCT03169231). In 148 ambulatory adults with aging frailty, six-minute walk distance versus placebo improved by 41.3 m at 6 months (95% CI -2.4 to 84.9, not significant) and by 63.4 m at 9 months (95% CI 17.1 to 109.6, P = 0.008), with a dose- and time-dependent pattern and no safety signal at this sample size. The caveats matter: 148 patients cannot detect rare harms, nine months is short, and the trial was company-run with NIA funding. The page is blunt that none of this transfers to the unregulated stem cell injections sold at wellness clinics, which is the version your patients will actually encounter.

    EVIDENCE PAGE UPDATED NOV 12: Peptide therapy: the tesamorelin meta-analysis, and why it does not transfer

    The peptide therapy page adds a 2026 systematic review and meta-analysis of five randomized trials of tesamorelin, a GHRH analogue approved for HIV-associated lipodystrophy. Pooled against placebo, visceral adipose tissue, trunk fat and liver fat fell and lean mass rose by about 1.4 kg (95% CI 1.13 to 1.71); BMI and subcutaneous fat did not change, and heterogeneity on the visceral fat estimate was high. Two earlier phase 3 trials (806 patients) showed a roughly 15% visceral fat reduction sustained to one year, higher IGF-1 and no clinically meaningful change in glucose control. The page frames this as a summary of published research in a specific approved indication: use for body composition or longevity in people without HIV lipodystrophy is off-label and investigational, and the popular compounded peptides (BPC-157, TB-500) rest mostly on animal data.

    Also refreshed this week

    Acetyl-L-carnitine (reviewed Nov 14): a June 2026 meta-analysis of 10 RCTs found a reduction in depressive symptoms (SMD -1.20) that was much larger in adults 60 and over (SMD -1.88) than under 60 (SMD -0.28), with I-squared near 97% and low certainty of evidence.

    Plasma ceramides (ceramide risk score): new biomarker entry covering the 0 to 12 score, risk bands, and the reported 1.4 to 1.7-fold MACE gradient independent of LDL-C. Not FDA-approved; read alongside apoB, Lp(a) and hs-CRP.

    Copper-to-zinc ratio: new entry on this inflammatory-nutritional marker in older adults, with the caveat that no universal clinical reference range exists.

    Lp(a)HORIZON is the most important negative trial of the year for primary care. Nothing about it changes the advice to measure Lp(a) once in adulthood: it remains an independent, inherited risk marker, and it tells you who to test in the family and how hard to push on everything else. What it does change is the conversation. Patients who read the headlines will ask whether the "Lp(a) drug" is coming. For now the honest answer is that the first one lowered the number by 78% and prevented nothing in secondary prevention, with real anaphylaxis risk, and the next trials read out in 2028 and 2029. In the meantime the levers with outcome data are the ones we already own: apoB, blood pressure, glycemia, smoking. That is less exciting and more useful.

    Longevity news worth your minute

    The Lp(a) pipeline continues despite pelacarsen. Amgen's olpasiran outcomes trial (OCEAN(a)-Outcomes, about 7,300 patients) lists primary completion around March 2028, and Lilly's lepodisiran trial (ACCLAIM-Lp(a), about 17,300 patients) is registered to complete in 2029. Both agents lowered Lp(a) more deeply than pelacarsen in phase 2, which is the main argument for not closing the book on the hypothesis.

    Guideline position is unchanged: measure Lp(a) at least once in adulthood. The National Lipid Association's commentary on the Lp(a)HORIZON top-line results makes the same point.

    Share this issue and stay subscribed

    If this was useful, forward it to a colleague or share it.

    Not subscribed yet?

    Warmly,

    Sanjeev Goel, MD

    Important disclaimer

    This newsletter is for educational purposes for licensed healthcare professionals and is not medical advice. It summarizes published research; it does not recommend, endorse or provide dosing for any compound or therapy, and several topics discussed are investigational, off-label or lack outcome trials. Outcome figures are attributed to the specific trials named. Use your own clinical judgment and consult primary sources.

    VIP Community

    Unlock Your Full Potential